Showing results (1531-1540 of 3,660) with videos related to
Sort By:
Pageof 366
Breast (Edinburgh, Scotland)|December 14, 2021
Development of novel agents for the treatment of early estrogen receptor positive breast cancerMitchell J Elliott, David W CesconBreast (Edinburgh, Scotland)|December 23, 2021
Effect of postmastectomy radiotherapy on pT1-2N1 breast cancer patients with different molecular subtypesXin-Yuan Guo, Guang-Yi Sun, Hong-Mei Wang, et al.Breast (Edinburgh, Scotland)|November 22, 2021
Nomogram for the personalisation of radiotherapy treatments in breast cancer patientsInmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo MaciasBreast (Edinburgh, Scotland)|October 29, 2022
The impact of standardized structured reporting of pathology reports for breast cancer careJ A A Snoek, I D Nagtegaal, S Siesling, et al.Breast (Edinburgh, Scotland)|November 3, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysisYouwen Zhu, Kun Liu, Min Wang, et al.Breast (Edinburgh, Scotland)|November 3, 2022
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapyJae Ho Jeong, Sung-Bae KimBreast (Edinburgh, Scotland)|November 6, 2022
Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancerEoin P Kerin, Matthew G Davey, Ray P McLaughlin, et al.Breast (Edinburgh, Scotland)|November 4, 2022
Acinic cell carcinoma of the breast: A comprehensive reviewAzra Ajkunic, Faruk Skenderi, Nada Shaker, et al.Breast (Edinburgh, Scotland)|September 16, 2022
Prognosis stratification and postoperative radiation therapy utilization in adenoid cystic carcinoma of the breastDi Zhang, Lixi Li, Fei MaBreast (Edinburgh, Scotland)|November 5, 2022
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancerElie Rassy, Layal Rached, Barbara PistilliPageof 366